BUSINESS

Japan Approves Pfizer’s Omicron-Tailored Vaccine for Ages 5-11

March 1, 2023

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Pfizer and BioNTech said on February 28 that they have obtained Japanese regulatory approval for their Omicron-targeted bivalent COVID-19 vaccine for booster use in children ages five to 11 years.The nod was granted in the form of an approval modification…

To read the full story

Pfizer’s Bivalent COVID Vaccines Approved for Primary Series in Japan
August 3, 2023
BA.4/5-Based Jab Filed for 6 Months to 4 Years in Japan: Pfizer/BioNTech
April 12, 2023
Japan Starts Omicron Vaccine Rollout for Ages 5-11
March 8, 2023
Pfizer’s Omicron-Adapted Jab for Ages 5-11 in Line for Japan Approval
February 28, 2023
Pfizer Seeks Japan Nod for BA.4/5-Tailored Vaccine for Ages 5-11
October 13, 2022

BUSINESS

Bayer/Santen to Launch Eylea Bio-AG on February 2
January 9, 2026
Nxera Bags Japan, Select APAC Rights to Santhera’s DMD Therapy
January 9, 2026
Keio Offshoot Taps Alfresa Know-How for Cell Therapy Push, Bets on Dual iPS Strategy
January 9, 2026
Asahi Kasei Sees Tarpeyo Uptake Outpacing Forecast, Peak Sales Can Be Higher
January 9, 2026
Rakuten Ramps Up Photoimmunotherapy PIII with Financing, Eyes US Filing in 2028
January 9, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Gist of FY2026 Drug Pricing Reform Outline

The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…

COMMENTARY

Wave of “World Firsts” Looms as 47 New Drug Candidates Line Up for 2026

By Shinya Sato

As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…